| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
264,900,000 |
| Market
Cap: |
8.27(B) |
| Last
Volume: |
49,305,461 |
Avg
Vol: |
5,854,790 |
| 52
Week Range: |
$4.32 - $31.23 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 606 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile ImmunoGen is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs). Co.'s main program is mirvetuximab, an ADC targeting folate receptor alpha, a cell-surface protein overexpressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Pivekimab sunirine is an ADC comprised of an antibody designed to target CD123 with site-specific conjugation to a DNA-alkylating payload of the IGN (indolinobenzodiazepine pseudodimer) class. Co.'s pipeline program, IMGC936, is an ADC that is designed to target ADAM9, an enzyme overexpressed in a range of solid tumors and implicated in tumor progression and metastasis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
39,348 |
1,060,446 |
4,785,085 |
4,785,085 |
| Total Sell Value |
$1,152,494 |
$23,992,060 |
$86,338,289 |
$86,338,289 |
| Total People Sold |
4 |
5 |
5 |
5 |
| Total Sell Transactions |
4 |
17 |
26 |
26 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lambert John |
Executive Vice President |
• – – |
2015-09-01 |
4 |
AS |
$13.16 |
$51,188 |
D/D |
(3,889) |
106,857 |
|
- |
|
| Lambert John |
Executive Vice President |
• – – |
2015-09-01 |
4 |
OE |
$3.19 |
$12,406 |
D/D |
3,889 |
110,746 |
|
- |
|
| Junius Daniel M |
Chief Executive Officer |
• • – |
2015-08-17 |
4 |
OE |
$5.77 |
$71,029 |
D/D |
12,310 |
154,115 |
|
- |
|
| Johnston David Brannon |
Chief Financial Officer |
• – – |
2015-08-03 |
4 |
AS |
$17.04 |
$85,180 |
D/D |
(5,000) |
0 |
|
- |
|
| Johnston David Brannon |
Chief Financial Officer |
• – – |
2015-08-03 |
4 |
OE |
$10.79 |
$53,950 |
D/D |
5,000 |
5,000 |
|
- |
|
| Junius Daniel M |
Chief Executive Officer |
• • – |
2015-08-03 |
4 |
AS |
$17.03 |
$92,247 |
D/D |
(5,416) |
141,805 |
|
- |
|
| Junius Daniel M |
Chief Executive Officer |
• • – |
2015-08-03 |
4 |
OE |
$3.19 |
$17,277 |
D/D |
5,416 |
147,221 |
|
- |
|
| Lambert John |
Executive Vice President |
• – – |
2015-08-03 |
4 |
AS |
$17.10 |
$66,509 |
D/D |
(3,889) |
106,857 |
|
- |
|
| Lambert John |
Executive Vice President |
• – – |
2015-08-03 |
4 |
OE |
$3.19 |
$12,406 |
D/D |
3,889 |
110,746 |
|
- |
|
| Junius Daniel M |
Chief Executive Officer |
• • – |
2015-07-01 |
4 |
AS |
$14.34 |
$77,676 |
D/D |
(5,416) |
141,805 |
|
- |
|
| Junius Daniel M |
Chief Executive Officer |
• • – |
2015-07-01 |
4 |
OE |
$3.19 |
$17,277 |
D/D |
5,416 |
147,221 |
|
- |
|
| Lambert John |
Executive Vice President |
• – – |
2015-07-01 |
4 |
AS |
$14.34 |
$55,769 |
D/D |
(3,888) |
106,857 |
|
- |
|
| Lambert John |
Executive Vice President |
• – – |
2015-07-01 |
4 |
OE |
$3.19 |
$12,403 |
D/D |
3,888 |
110,745 |
|
- |
|
| Onetto Nicole |
Director |
– • – |
2015-06-15 |
4 |
S |
$13.86 |
$44,495 |
D/D |
(3,211) |
0 |
|
- |
|
| Onetto Nicole |
Director |
– • – |
2015-06-15 |
4 |
OE |
$7.82 |
$25,110 |
D/D |
3,211 |
3,211 |
|
- |
|
| Lambert John |
Executive Vice President |
• – – |
2015-06-01 |
4 |
AS |
$11.78 |
$176,636 |
D/D |
(15,000) |
106,857 |
|
- |
|
| Lambert John |
Executive Vice President |
• – – |
2015-06-01 |
4 |
OE |
$5.35 |
$80,250 |
D/D |
15,000 |
121,857 |
|
- |
|
| Junius Daniel M |
Chief Executive Officer |
• • – |
2015-05-07 |
4 |
S |
$8.02 |
$9,744 |
D/D |
(1,215) |
141,805 |
|
- |
|
| Junius Daniel M |
Chief Executive Officer |
• • – |
2015-05-07 |
4 |
OE |
$5.74 |
$6,974 |
D/D |
1,215 |
143,020 |
|
- |
|
| Junius Daniel M |
Chief Executive Officer |
• • – |
2015-05-04 |
4 |
OE |
$5.74 |
$61,114 |
D/D |
10,647 |
141,805 |
|
- |
|
| Junius Daniel M |
Chief Executive Officer |
• • – |
2015-05-01 |
4 |
AS |
$8.36 |
$295,198 |
D/D |
(35,315) |
131,158 |
|
- |
|
| Junius Daniel M |
Chief Executive Officer |
• • – |
2015-05-01 |
4 |
OE |
$5.74 |
$202,708 |
D/D |
35,315 |
166,473 |
|
- |
|
| Lambert John |
Executive Vice President |
• – – |
2015-05-01 |
4 |
AS |
$8.32 |
$83,184 |
D/D |
(10,000) |
106,857 |
|
- |
|
| Lambert John |
Executive Vice President |
• – – |
2015-05-01 |
4 |
OE |
$5.35 |
$53,500 |
D/D |
10,000 |
116,857 |
|
- |
|
| Junius Daniel M |
Chief Executive Officer |
• • – |
2015-04-21 |
4 |
OE |
$5.74 |
$40,002 |
D/D |
6,969 |
131,158 |
|
- |
|
257 Records found
|
|
Page 10 of 11 |
|
|
